Cochrane find no evidence for as required PRN medication for mental health...
John Baker summarises an updated Cochrane review on 'as required' PRN medication regimens for seriously mentally ill people in hospital, which finds no randomised controlled trials that support this...
View ArticleAntipsychotic overprescribing in people with learning disabilities...
Tayla McCloud from the #UCLJournalClub presents the findings of a cohort study showing that antipsychotics are being over-prescribed in people with learning disabilities. The post Antipsychotic...
View ArticleThe delirium conundrum: are antipsychotics a good idea?
Andres Fonseca struggles to use the findings of a recent systematic review and meta-analysis of antipsychotics for the prevention and treatment of delirium in hospitalised adults. The post The delirium...
View ArticleTrends in antipsychotic prescribing in autism
Angela Hassiotis and James Dove summarise a recent meta-analysis of antipsychotic prescribing and use trends in US youth with autism spectrum disorder and/or learning disabilities. The post Trends in...
View ArticleEvidence-based guidelines for treating bipolar disorder
Joseph Hayes summarises the recent British Association for Psychopharmacology guidelines for the treatment of bipolar disorder, and compares their recommendations with those found in the NICE bipolar...
View ArticleITI-007 for schizophrenia
Murtada Alsaif summarises a recent 4-week long phase II randomised controlled trial of ITI-007 for the treatment of schizophrenia, which contains some positive results for this novel intervention. The...
View ArticleAdding antidepressants to antipsychotics in schizophrenia: do they work, for...
Alex Langford explores the emerging findings from a recent meta-analysis looking at the efficacy and safety of antidepressants added to antipsychotics for people with schizophrenia and...
View ArticleSchizophrenia, antipsychotics and quality of life: measuring the important...
Samei Huda mulls over a recent RCT on the effects of older and newer antipsychotics on quality of life in schizophrenia. The study finds a different result to the 10-year old CUTLASS trial; namely that...
View ArticleIt’s a jungle out there: the natural history of behavioural and psychological...
Caroline Struthers scrutinises a systematic review on the longitudinal course of behavioural and psychological symptoms of dementia. The post It’s a jungle out there: the natural history of behavioural...
View ArticleThe side-effects of antipsychotics: let’s systematically assess, discuss and...
A live blog published at the 22nd International Network for Psychiatric Nursing Research conference in Nottingham. Written by John Baker, Lucy Brazener, Wendy Cross, Vanessa Garrity, Andrew Grundy,...
View ArticleBipolar disorder in older men linked to increased risk of dementia
Elena Marcus presents a recent study that shows how older Australian men with bipolar disorder have an increased risk of dementia and early death. The post Bipolar disorder in older men linked to...
View ArticleDepot antipsychotics: If you pay me, you can keep injecting me
John Baker looks at the 2-year follow-up results of a cluster RCT on the effectiveness of financial incentives to improve adherence to maintenance treatment with depot antipsychotics. The post Depot...
View ArticleAntipsychotic efficacy measured by real-world observational study
Tracey Roberts examines whether a retrospective observational study accurately investigates the effectiveness of second and first generation antipsychotics. The post Antipsychotic efficacy measured by...
View ArticleRisperidone versus placebo for people with schizophrenia
Joanne Wallace summarises the recent Cochrane systematic review on risperidone versus placebo for schizophrenia, which concludes that the best available evidence does not show that the benefits of...
View ArticleAntipsychotics for delirium in palliative care: new RCT suggests non-drug...
Samei Huda highlights a recent RCT of antipsychotics (risperidone and haloperidol) versus placebo for symptoms of delirium in palliative care, which suggests we need non-drug alternatives for this...
View ArticleAntidepressants for bipolar depression: weighing up the benefits and harms
Murtada Alsaif considers a recent systematic review on the safety and efficacy of adjunctive second-generation antidepressant therapy with a mood stabiliser or an atypical antipsychotic in acute...
View ArticlePsychotropic medication: finding ways forward for adults with intellectual...
Rory Sheehan and Angela Hassiotis discuss how to optimise psychotropic medication for people with intellectual disabilities; the theme of their #RSMpsychotropics conference taking place in London...
View ArticleShould people with schizophrenia be offered depot antipsychotics as first...
Murtada Alsaif reports on a new nationwide Swedish cohort study that explores the real-world effectiveness of oral and depot antipsychotics for people with schizophrenia. The post Should people with...
View ArticleMedication for mental health: Oral health impacts
This review of the side effects of medications prescribed for the management of mental health highlights their potential impact on oral health. The commonest problems being xerostomia. The post...
View ArticleAntipsychotics for acute treatment of first episode schizophrenia
Elwira Lubos writes her debut blog on a recent systematic review with pairwise and network meta-analyses, looking at antipsychotic drugs for the acute treatment of patients with first episode...
View Article